X
CTKB icon

Xponance’s Cytek Biosciences CTKB Stock Holding History

Xponance’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.3K Buy
+10,593
New +$50K ﹤0.01% 1636

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Xponance's CTKB Position: Q1 2026 in Review

Xponance opened a new position in Cytek Biosciences (CTKB) in Q1 2026: 10,593 shares worth $46.3K. The stake represents ﹤0.01% of the portfolio and ranks #1636 among its holdings.

165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Xponance held 10,593 shares of Cytek Biosciences worth $46.3K as of Q1 2026.
  • Cytek Biosciences was a new Xponance position in Q1 2026.
  • Cytek Biosciences made up ﹤0.01% of Xponance's portfolio in Q1 2026, its #1636 holding.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.